Follow the start of trading for InDex Pharmaceuticals live

Update: a recording of the broadcast is now available and can be viewed afterwards via the link below or by clicking on the image.
Great interest in record-breaking IPO issue
As the finale of one of the largest biotech IPOs in recent years, with a listing issue of a whopping SEK 250 million, InDex Pharmaceuticals is today making its debut on the Stockholm Stock Exchange where it is listed on Nasdaq First North. Interest in the listing has been great – over five thousand new shareholders chose to subscribe to the issue.
Filling the coffers with a quarter of a billion
The entire issue amount of SEK 250 million was guaranteed through subscription commitments and underwriting. When the outcome of the issue was announced, it was revealed that the equivalent of SEK 95,3 million was subscribed by the public and institutional investors, SEK 111 million was subscribed under subscription commitments and the remaining SEK 43,7 million was subscribed under underwriting commitments.
Promising lead drug candidate in late clinical phase
InDex Pharmaceuticals develops drugs for immunological diseases and is in late clinical phase with its lead drug candidate cobitolimod for moderate to severe ulcerative colitis, a difficult-to-manage inflammatory bowel disease that currently lacks a curative treatment. The company has conducted four clinical studies with its substance and has promising results in terms of both efficacy and safety profile. A planned phase IIb study is now pending, where the goal is to maximize the effect of cobitolimod by testing the optimal dosage and dose frequency.
Further positive study results to be presented in Vienna
Yesterday it was announced that further analyses of data from the company's latest clinical trial, the so-called COLLECT study, will be presented during the United European Gastroenterology Week (UEGW) 15-19 October in Vienna. The analyses indicate that cobitolimod can induce clinical remission in patients with both moderate and severe ulcerative colitis. The positive results will be presented both orally and as posters during the UEGW, which is the largest scientific meeting for gastroenterologists in Europe.
Cobitolimod – a potential blockbuster upon market approval
InDex Pharmaceuticals itself expects that cobitolimod, after possible market approval, should be able to become a so-called blockbuster, with annual sales exceeding $1 billion. The company has a stated goal of finding a development partner to conduct a larger phase III study, the final step in the development process before commercialization, provided that the planned phase IIb study shows positive results.
The live broadcast starts at 08.40:XNUMX AM.
Follow the events surrounding the listing and initial trading on InDex Pharmaceuticals' first trading day live here. The broadcast, which is being made in collaboration with Nyhetsbyrån Direkt, starts at 08.40.
Click here to access the live broadcast of InDex Pharmaceuticals' trading launch.